Table 1 Expansion of TILs from Ovarian Cancer Tumors.
Sample ID | Previous anti-CTLA-4 treatment | Condition | Number of fragments | Total TIL number (×106) | TILs per fragment (×106) | Expansion time (Days) |
|---|---|---|---|---|---|---|
GY1508.05 | No | IL-2 | 4 | 0.1 | 0.03 | 35 |
IL-2 + anti-CTLA-4 | 4 | 31.2 | 7.8 | 35 | ||
GY1508.06 | No | IL-2 | 10 | 20 | 2 | 30 |
IL-2 + anti-CTLA-4 | 10 | 196 | 19.6 | 28 | ||
GY1508.07 | No | IL-2 | 6 | 0 | 0 | 32 |
IL-2 + anti-CTLA-4 | 6 | 37 | 6.17 | 32 | ||
GY1508.08 | No | IL-2 | 8 | 38 | 4.75 | 33 |
IL-2 + anti-CTLA-4 | 8 | 16.1 | 2.01 | 33 | ||
GY1508.09 | No | IL-2 | 8 | 0 | 0 | 25 |
IL-2 + anti-CTLA-4 | 8 | 6.4 | 0.80 | 32 | ||
GY1508.10 | No | IL-2 | 8 | 24.2 | 3.03 | 28 |
IL-2 + anti-CTLA-4 | 8 | 72.4 | 9.05 | 26 | ||
GY1508.11 | No | IL-2 | 8 | 74 | 9.25 | 26 |
IL-2 + anti-CTLA-4 | 4 | 41 | 10.25 | 26 | ||
EOC.TIL.27 | No | IL-2 | 12 | 15.4 | 1.28 | 35 |
IL-2 + anti-CTLA-4 | 12 | 90 | 7.50 | 35 | ||
GY1721.01 | Yes | IL-2 | 8 | 84.9 | 10.61 | 18 |
IL-2 + anti-CTLA-4 | 8 | 117.6 | 14.70 | 18 | ||
GY1721.02 | Yes | IL-2 | 8 | 21.7 | 2.71 | 32 |
IL-2 + anti-CTLA-4 | 8 | 120.7 | 15.09 | 30 | ||
GY1721.03 | Yes | IL-2 | 8 | 180.2 | 22.53 | 21 |
IL-2 + anti-CTLA-4 | 8 | 224.9 | 28.11 | 21 | ||
GY1721.04 | Yes | IL-2 | 8 | 56.7 | 7.09 | 25 |
IL-2 + anti-CTLA-4 | 8 | 100.2 | 12.53 | 22 | ||
GY1721.05 | Yes | IL-2 | 8 | 84.5 | 10.56 | 16 |
IL-2 + anti-CTLA-4 | 8 | 56.2 | 7.03 | 16 | ||
GY1721.07 | Yes | IL-2 | 4 | 4.2 | 1.04 | 36 |
IL-2 + anti-CTLA-4 | 6 | 97.9 | 16.32 | 36 |
